Compare MDGL & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | PEN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.9B |
| IPO Year | 2005 | 2015 |
| Metric | MDGL | PEN |
|---|---|---|
| Price | $514.87 | $329.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $674.45 | $357.33 |
| AVG Volume (30 Days) | 349.8K | ★ 543.5K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.32 | ★ 1155.56 |
| EPS | N/A | ★ 4.52 |
| Revenue | $180,133,000.00 | ★ $1,403,665,000.00 |
| Revenue This Year | $58.39 | $14.34 |
| Revenue Next Year | $47.10 | $13.71 |
| P/E Ratio | ★ N/A | $72.88 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $265.00 | $221.26 |
| 52 Week High | $615.00 | $362.41 |
| Indicator | MDGL | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.11 | 37.51 |
| Support Level | $411.87 | $326.58 |
| Resistance Level | $610.00 | $338.99 |
| Average True Range (ATR) | 26.99 | 2.24 |
| MACD | 3.28 | -0.22 |
| Stochastic Oscillator | 58.82 | 25.65 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.